NCT02659241 2026-04-15
Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
Clinical Trials
17 trialsNCT02513563 2026-02-19
AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03579316 2026-02-18
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT03668340 2026-01-12
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03028766 2024-09-19
WISTERIA
University of Birmingham
Phase 1 Completed
NCT01164995 2023-09-07
M10MKO
The Netherlands Cancer Institute
Phase 2 Completed
NCT02576444 2022-12-28
OLAPCO
Yale University
Phase 2 Terminated
NCT05212025 2022-06-14
Adavosertib and Gemcitabine in Advanced Pancreatic
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT03012477 2021-11-23
CISPLATIN + AZD-1775 In Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02585973 2021-06-29
Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT02593019 2021-03-19
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients
Samsung Medical Center
Phase 2 Completed
NCT02207010 2020-12-10
A Phase 0 Study of AZD1775 in Recurrent GBM Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Completed
NCT02906059 2020-10-12
Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer
NYU Langone Health
Phase 1 Completed
NCT02666950 2019-09-06
WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Mayo Clinic
Phase 2 Completed
NCT02508246 2019-03-13
WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck
University of Washington
Phase 1 Completed
NCT02688907 2018-09-20
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation
Samsung Medical Center
Phase 2 Terminated